Dold, Markus http://orcid.org/0000-0001-8914-2192
Bartova, Lucie
Volz, Hans-Peter
Seifritz, Erich
Möller, Hans-Jürgen
Schläfke, Sandra
Kasper, Siegfried
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 7 July 2022
Accepted: 19 December 2022
First Online: 30 January 2023
Declarations
:
: MD has received travel grants and consultant/speaker honoraria from Medizin Medien Austria and Janssen. Within the last three years, LB has received travel grants and consultant/speaker honoraria from Medizin Medien Austria, Universimed, Schwabe Austria, Janssen and Angelini. Within the last three years, HPV has served as a consultant or on advisory boards for Astra/Zeneca, Eli Lilly, Lundbeck, Pfizer, Schwabe, Janssen, Otsuka, Angelini, and Sage and has served on speakers’ bureaus for Astra/Zeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Bayer, Recordati and neuraxpharm. ES received in the last three years honoraria and grants for advice and educational lectures from Lundbeck Switzerland, Schwabe Switzerland and Germany, Janssen Switzerland, Otsuka Switzerland, Mepha Pharma Switzerland, Otsuka Pharma Switzerland, Ricordati Switzerland and Sunovion Pharma UK and Angelini. HJM has received grant/research support, consulting fees and honoraria within the last years from AstraZeneca, Lundbeck, Otsuka, and Schwabe. SS is employee of Dr. Willmar Schwabe GmbH & Co. KG. SK has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speakers bureaus for Aspen Farmaceutica S.A., Angelini, Biogen, Janssen, Lundbeck, Neuraxpharma, Recordati, Sage, Sanofi, Schwabe, Servier and Sun Pharma.